• NeoGenomics, Inc. previously completed an internal investigation into certain consulting and service agreements and, in June 2026, finalized a civil settlement with the U.S. Department of Justice, agreeing to pay US$9,813,260 plus 4.250% annual interest, after having reserved US$11.20 million for potential liabilities.
• The settlement, which involves no admission of liability, removes an overhang related to federal healthcare compliance just as NeoGenomics expands its oncology test menu, including an FDA-approved PTEN IHC companion diagnostic for prostate cancer.
• We’ll now consider how resolving the DOJ investigation, with reserved funds exceeding the settlement amount, may reshape NeoGenomics’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

NeoGenomics Investment Narrative Recap

To own NeoGenomics, you need to believe in the long term demand for specialized oncology testing and the company’s ability to turn its expanding test menu into profitable growth, despite current losses and a relatively high valuation. The DOJ settlement appears manageable in size given prior reserves and mainly clears a compliance overhang; near term, execution on new test adoption and managing high fixed costs still look like the key catalyst and the biggest risk.

The recent launch of the FDA approved PTEN IHC companion diagnostic for prostate cancer ties directly into that catalyst, underscoring NeoGenomics’ push into higher value, precision oncology testing. How quickly clinicians incorporate PTEN IHC and the broader PanTracer portfolio into routine practice may matter more for the story than the one time legal payment, but both developments sit in the background as the company approaches its upcoming Q2 2026 earnings update.

Yet against this product momentum, investors should be aware of the ongoing risk that legal and regulatory issues could still...

NeoGenomics' narrative projects $982.4 million revenue and $63.1 million earnings by 2029.

Uncover how NeoGenomics' forecasts yield a $16.22 fair value, a 23% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting NeoGenomics to reach about US$1.0 billion in revenue and US$12.0 million in earnings by 2029, which is far rosier than consensus. In light of the DOJ settlement and the ongoing risk of concentrated reliance on large pharma and institutional clients, you may find your own view sits anywhere along a wide spectrum of opinions that could shift as this new information is absorbed.

Explore 2 other fair value estimates on NeoGenomics - why the stock might be worth just $16.22!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your NeoGenomics research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free NeoGenomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NeoGenomics' overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.